EL219
Sponsors
Elion Therapeutics Inc., Elion Therapeutics, Inc.
Conditions
Invasive Mould InfectionSuspected Invasive Mould Infection
Phase 2
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
RecruitingNCT07215273
Start: 2026-02-13End: 2026-12-01Target: 60Updated: 2026-09-16
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 versus Standard of Care (Liposomal Amphotericin B followed by Voriconazole) for Early Antifungal Therapy of Suspected Invasive Mould Infections
Not yet recruitingCTIS2025-522835-32-00
Target: 54Updated: 2026-02-27